Theacrine vs Caffeine

They are both methylated purine alkaloids that keep you awake, which is why they get lumped together. Their chemistry, their duration, and the way researchers have tested them are not the same — and that difference is the whole subject of this guide.

Reading time ~9 min · Evidence reviewed: acute human trials · Last updated February 2026

1. What each one actually is

Caffeine is 1,3,7-trimethylxanthine — the most widely consumed psychoactive substance on earth. Its main mechanism is well characterised: at typical dietary doses it blocks adenosine receptors (A1 and A2A), which reduces the sleep-pressure signal and indirectly increases dopamine signalling. Caffeine is found in coffee, tea, cola, and thousands of supplements, and its pharmacokinetics are unusually well studied.

Theacrine is 1,3,7,9-tetramethyluric acid — a methyluric acid, not a xanthine. It occurs naturally in Camellia assamica var. kucha, a tea plant grown in parts of southern China, and the material used in research is now produced synthetically as a nature-identical molecule (sold under the brand name TeaCrine®). Structurally it looks like caffeine with an extra methyl group and a different core ring, and that small change produces a noticeably different pharmacological profile.

The distinction matters because "theacrine is caffeine's cousin" is where most of the confusion starts. The two are related by structure, not interchangeable in effect.

2. Side-by-side comparison

The table below reflects what the published literature supports as of this review. Where the evidence is thin, it says so.

"No significant change" means not detected in the specific trial, at that dose, in that population. It is not proof of cardiovascular safety, especially at repeated higher doses.

3. What the combination trial actually measured

The most-cited study in this area tested three conditions in healthy adults: a combination of 150 mg caffeine + 150 mg theacrine (a 1:1 blend, referred to as CTC), 300 mg caffeine alone, and a placebo. Supplementation was timed about 60 minutes before the exercise task. The materials were supplied by Compound Solutions, the TeaCrine® patent holder, and third-party tested by Dyad Labs — a detail worth noting, because it means both actives were verified rather than assumed.

Participants completed cognitive testing before supplementation, after supplementation, and after fatiguing exercise — including an immediate post-exercise point and 30 minutes later. The battery included anti-saccade tasks (a measure of inhibitory control and visual attention) and a 2-back working-memory task.

Three results are the ones that get quoted:

• Sustained attention under fatigue. At 30 minutes post-exercise, the 1:1 blend showed lower reaction-time variability on the anti-saccade task than both caffeine alone and placebo — roughly 35% lower than caffeine and 49% lower than placebo. Variability is the interesting metric here: it tracks consistency of attention, not just raw speed.
• Working-memory accuracy. On the 2-back task, the blend improved accuracy by about 7.3% versus placebo, while the caffeine-alone arm did not reach statistical significance against placebo on that measure.
• No cardiovascular cost. Neither the blend nor caffeine significantly changed heart rate or heart-rate variability in this trial — meaning the cognitive benefit was not simply coming from a bigger stimulant load.

The study's own conclusion is more careful than the marketing that followed it: the authors describe the combination as improving several cognitive measures before and after fatiguing exercise, and suggest that pairing a lower caffeine dose with theacrine may produce equal or greater cognitive benefit than a higher caffeine dose alone. They also explicitly call for future work on higher theacrine doses, chronic supplementation, longer exercise, and different cognitive tests — which is a fair statement of how little the single trial settles.

4. Why the blend is not just "more caffeine"

A reasonable objection: if you take two stimulants together, of course you get more stimulation. The pharmacokinetic work argues against that being the whole explanation.

A 2017 study by He and colleagues examined co-administration of caffeine and theacrine. Co-dosing around 150 mg caffeine raised theacrine's peak plasma concentration and total exposure (area under the curve) — without producing corresponding changes in heart rate or blood pressure. In other words, caffeine appears to alter how much theacrine is available, not merely to add its own adenosine blockade on top.

That has two implications for reading this literature. First, the 1:1 blend is not pharmacologically equivalent to "150 mg of each taken separately" — the interaction is part of the intervention. Second, it explains how a 1:1 blend totalling 300 mg of active material behaved differently from 300 mg of caffeine alone, despite the identical total milligram figure.

5. What this research does not show

This is the section most supplement pages omit, so here it is in full.

• It does not show that theacrine "replaces" caffeine. The blend contained caffeine. There is no equivalent evidence that theacrine alone matches caffeine on alertness.
• It does not establish chronic benefit. The measured effects are acute, single-session effects. Whether they persist, fade, or change with repeated use is not answered here.
• It does not generalise automatically. Participants were healthy adults in a controlled setting with a fast before testing and other caffeine controlled. Shift workers, people with anxiety disorders, people on medication, and older adults were not the study population.
• Statistical significance is not a large effect. A 7.3% accuracy difference on a working-memory task is measurable and real within the study — it is not a transformation of cognitive ability.
• Absence of cardiovascular change in one trial is not a safety finding. It is one observation, at one dose, over a few hours.
• Task-specificity cuts both ways. Anti-saccade and 2-back tasks are good measures, but performing better on them is not the same as performing better at your job.

6. Safety differences that matter

Caffeine's risk profile is well known and dose-dependent: insomnia, anxiety, palpitations, gastrointestinal upset, and at high acute doses tremor, arrhythmia, and — for anhydrous powder — a genuine risk of accidental overdose. Guidance for healthy adults generally places total intake well below the levels used in performance studies, and pregnancy, cardiovascular disease, and several drug classes change the picture entirely.

Theacrine's profile is less established simply because it has been studied less. The longest commonly cited repeated-dose work used 300 mg per day for 8 weeks with no adverse clinical markers or habituation reported — which is reassuring as far as it goes, and no substitute for long-term data. Its longer duration also means it is a poor choice late in the day if sleep matters to you.

7. Common questions

Sources and how to read them

• Acute trial of caffeine 150 mg + theacrine 150 mg versus caffeine 300 mg versus placebo, with cognitive testing before and after fatiguing exercise; materials supplied by Compound Solutions (TeaCrine®), third-party tested by Dyad Labs.
• He et al. (2017), pharmacokinetic evaluation of caffeine and theacrine co-administration — the basis for the claim that caffeine raises theacrine exposure without changing heart rate or blood pressure.
• Repeated-dose theacrine work at 300 mg/day for 8 weeks, reporting no adverse clinical markers or habituation.
• General caffeine safety guidance from national food-safety and health authorities, including pregnancy and cardiovascular cautions.

We summarise rather than reproduce these papers, and we name brand holders only to identify the materials used. If you spot an error in our summary, tell us and we will correct it.

← Back to the hub